<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576247</url>
  </required_header>
  <id_info>
    <org_study_id>19-3032.cc</org_study_id>
    <nct_id>NCT04576247</nct_id>
  </id_info>
  <brief_title>Combined Modality Exercise and Appetite in Breast Cancer Survivors</brief_title>
  <acronym>CARE</acronym>
  <official_title>Feasibility, Acceptability, and Effects of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors: A Pilot Study (the CARE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Colorado Clinical &amp; Translational Sciences Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this research is to assess the feasibility of a 12-week combined aerobic&#xD;
      exercise (AEx) and resistance exercise (REx) intervention and elucidate the impact of AEx/REx&#xD;
      on several physiological and behavioral components of energy balance among breast cancer&#xD;
      survivors (BCS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Masking is not possible because this is a single-arm exercise study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment and enrollment feasibility</measure>
    <time_frame>Through study completion, up to two years</time_frame>
    <description>Number of individuals approached, meeting inclusion criteria, reasons for exclusion, and enrolled in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective exercise adherence</measure>
    <time_frame>Changes across weeks 4, 8, and 12</time_frame>
    <description>Participants will be asked to rate on a 1-10 Likert scale: 1) how adherent they were to the prescribed exercise over the past week, 2) how difficult it was to adhere to the prescribed exercise over the past week, and 3) how likely they feel they can adhere to the prescribed exercise for the next month.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise self efficacy</measure>
    <time_frame>Changes across weeks 4, 8, and 12</time_frame>
    <description>Self Efficacy for Exercise Scale; 9 items; score range: 0-9, with higher scores indicating higher exercise self-efficacy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise enjoyment</measure>
    <time_frame>Changes across weeks 4, 8, and 12</time_frame>
    <description>Physical Activity Enjoyment Scale; 8 items; range: 7-56, with higher scores indicating higher exercise enjoyment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Subjective ability to adhere to combined AEx/REx</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Barriers to completing AEx/REx</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Open-ended opinions on the structure and content of the exercise training sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in subjective physical function, cancer-specific side effects, and overall well-being directly related to the exercise intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective exercise adherence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adherence to additional study-specific AEx will be tracked through heart rate monitor data, logs of attendance, and participant diaries and compared to the REx-only intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in ghrelin</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Fasting ghrelin, ghrelin area under the curve in response to a control meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peptide-YY (PYY)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Fasting PYY, PYY area under the curve in response to a control meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in subjective appetite ratings</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Changes in hunger, satiety, and prospective food consumption via visual analog scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ad libitum energy intake</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Energy intake from buffet-style meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical activity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Step count measured by accelerometers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sedentary behavior</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Time in sedentary activities measured by accelerometers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in resting energy expenditure</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Resting energy expenditure measured by metabolic cart and adjusted for body composition changes</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in body composition</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Fat mass and fat-free mass in kg, measured by dual X-ray absorptiometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in fatigue</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Measured by the Functional Assessment of Chronic Illness and Therapy - Fatigue; 13 questions; score range: 0-52, with higher score indicating higher fatigue</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Combined aerobic and resistance exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of supervised resistance exercise and unsupervised aerobic exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Combined aerobic and resistance exercise</intervention_name>
    <description>The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.&#xD;
The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program.</description>
    <arm_group_label>Combined aerobic and resistance exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female sex&#xD;
&#xD;
          -  Age: 18 - 45 years&#xD;
&#xD;
          -  Body mass index [BMI]: 25 - 35 kg/m2&#xD;
&#xD;
          -  Pre-menopausal before cancer diagnosis and treatment&#xD;
&#xD;
          -  &lt;1 hour/week of planned physical activity by self-report in the previous 12 months&#xD;
&#xD;
          -  Diagnosis of primary stage I - III estrogen receptor/progesterone receptor-positive&#xD;
             (ER/PR+) breast cancer, according to institutional standards.&#xD;
&#xD;
          -  All chemotherapy, radiation, and surgery completed at least two weeks (14 days), but&#xD;
             less than 6 months prior to registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Self-reported diabetes mellitus, untreated/uncontrolled thyroid disease, history of&#xD;
             cardiovascular disease or symptoms suggestive of cardiovascular disease (chest pain,&#xD;
             shortness of breath at rest or with mild exertion, syncope), cancer diagnosis in the&#xD;
             last 5 years before breast cancer (any site, excluding skin cancer), or any other&#xD;
             medical condition affecting weight or energy metabolism.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as: systolic blood pressure &gt;160 mmHg or diastolic&#xD;
             blood pressure &gt;100mmHg, as measured during the screening visit. Participants who are&#xD;
             deemed ineligible based upon uncontrolled hypertension criteria will be referred to&#xD;
             their primary care physicians for treatment. If this condition becomes controlled they&#xD;
             will be allowed to be re-evaluated for inclusion in the current trial.&#xD;
&#xD;
          -  Unable to exercise due to cardiac, pulmonary, neurological, orthopedic reasons.&#xD;
&#xD;
          -  Currently smoking and/or nicotine use.&#xD;
&#xD;
          -  Treatment with medications known to significantly affect appetite, weight, energy&#xD;
             intake or expenditure in the last 3 months (e.g. appetite suppressants, lithium,&#xD;
             stimulants, anti-psychotics, tricyclic antidepressants).&#xD;
&#xD;
          -  Corticosteroid use within the last two weeks&#xD;
&#xD;
          -  History of surgical procedure for weight loss at any time (e.g. gastroplasty, gastric&#xD;
             bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve);&#xD;
             history of extensive bowel resection for other reasons&#xD;
&#xD;
          -  Currently pregnant, lactating or less than 6 months post-partum.&#xD;
&#xD;
          -  Score of â‰¥ 2 on the CAGE (cut-annoyed-guilty-eye opener) questionnaire adapted to&#xD;
             include drug use55&#xD;
&#xD;
          -  Score of &gt; 20 on the Eating Attitude Test - 26 (EATS-26), indicative of disordered&#xD;
             eating. Participants with a score &gt;20 on the EATS-26 will be referred to their primary&#xD;
             care physician for further evaluation.&#xD;
&#xD;
          -  Significant food intolerances/allergies that cannot be accommodated by the University&#xD;
             of Colorado Hospital Clinical Translational Research Center Metabolic Kitchen.&#xD;
&#xD;
          -  Currently participating in any formal weight loss or physical activity programs or&#xD;
             clinical trials for weight loss.&#xD;
&#xD;
          -  Other medical, psychiatric, or behavioral limitations that may interfere with&#xD;
             participation (as determined by study physician).&#xD;
&#xD;
          -  Unable or unwilling to undergo study procedures&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah A Purcell, PhD</last_name>
    <phone>3032651695</phone>
    <email>sarah.purcell@cuanschutz.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah A Purcell</last_name>
      <phone>303-265-1695</phone>
      <email>sarah.purcell@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah A Purcell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80238</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah A Purcell, PhD</last_name>
      <phone>303-265-1695</phone>
      <email>sarah.purcell@cuanschutz.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

